AlphaYouCBIO: Pinkas Jan discloses a sale
By AlphaYouPublished Form 4
Pinkas Jan
Reporting filer
Pinkas Jan reported Sale in CRESCENT BIOPHARMA, INC.: 658 units of Ordinary Shares, dated 2026-09-16. The full Form 4 contains 1 transaction entry.
- Disclosed
- Sep 18, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Pinkas Jan | 2026-09-16 | S | Sale | 658 | 17.90 | 21,581 | 2 days | Filed terms
|
Ordinary Shares
- Owner
- Pinkas Jan
- Date
- 2026-09-16
- Code
- S
- Action
- Sale
- Quantity
- 658
- Price
- 17.90
- Following holdings
- 21,581
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Ordinary Shares
- transaction Date: 2026-09-16
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: 0
- transaction Shares: 658
- id: F1
- transaction Price Per Share: 17.90
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 21581
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Pinkas Jan: Chief Scientific Officer.
- The filing reports a Rule 10b5-1 trading plan.
- F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 26, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Original sources
Prepared automatically from public filing data. Report a correction.